Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with Pharmaxis, may move into Phase 2 trials. Synairgen and Pharmaxis began their collaboration in 2015 to develop…
News
Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…
Blocking the platelet-derived growth factor receptor-beta (PDGFR-β) prevents lung fibrosis in a mice model of pulmonary fibrosis, a study says. Based on these observations, scientists believe that PDGFR-β blockade may someday be a viable therapeutic option for patients with idiopathic pulmonary fibrosis (IPF). The findings of the study, “Blockade…
A new subtype of immune cells carrying a unique genetic profile was identified and found to have an important role in the progression of fibrosis in the lungs, a study reports. The study, “Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage,” was published in…
A small Phase 1 pilot study found improved physical function in idiopathic pulmonary fibrosis (IPF) patients treated with senolytic therapies. The trial was conducted by researchers at University of Texas Health San Antonio, in collaboration with the Mayo Clinic and the Wake Forest School of Medicine. The findings…
Evaluating the lung area that is normal, or healthy, can help predict the survival of patients with combined pulmonary fibrosis and emphysema (CPFE) at the time of lung cancer diagnosis, according to a new study. The research, “Reduced area of the normal lung on high-resolution computed tomography…
One year of treatment with Genentech‘s Esbriet (pirfenidone) significantly reduced the incidence of disease progression events — including decline in lung function and physical capacity, respiratory-related hospitalizations, and death — in people with idiopathic pulmonary fibrosis…
A Phase 1 trial shows that combining Sprycel (dasatinib) with the plant-based flavonoid quercetin improved the physical function of people with idiopathic pulmonary fibrosis (IPF). However, patients’ pulmonary function remained unchanged. The study, “Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study” was published…
A Phase 1 trial of an investigational treatment for idiopathic pulmonary fibrosis (IPF), PLN-74809, has dosed a first group of healthy participants, Pliant Therapeutics announced. PLN-74809, the company’s lead candidate, is a small molecule that selectively inhibits both alphaVβ1 and αVβ6 integrins. These proteins mediate cell adhesion and are specific for…
Promedior plans to begin Phase 3 testing of its investigational therapy PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF), now that the U.S. Food and Drug Administration has signed off on the trial design, the biotechnology company announced. The agreement was reached in an end-of-Phase-2 meeting between…
